In Section C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, participants will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually ailment progression or maybe the individuals are not able to tolerate the study drugs. For all flow cytometry experi